Study wrapper · #507
The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.
Editor's note
This is a small double-blind, placebo-controlled pilot trial (22 adults) of low-dose tesamorelin, a growth hormone-releasing hormone (GHRH) analog, tested for effects on cognition and brain connectivity across a spectrum from normal cognition to mild cognitive impairment. Researchers reported that 10 weeks of low-dose (1 mg) tesamorelin was not associated with statistically significant changes in the prespecified measures of body composition, cognition, sleep, or imaging. Using exploratory machine-learning analysis, the authors identified possible treatment-related differences in specific brain regions. Weigh this cautiously: the trial was a pilot, underpowered, used a lower dose than the approved 2 mg, and the imaging signals are hypothesis-generating rather than confirmatory. It sits at the periphery of tesamorelin's established evidence base, which centers on visceral-fat reduction in HIV-associated lipodystrophy.
Plain-language abstract
In a pilot study, 22 adults whose thinking skills ranged from normal to mildly impaired were randomly assigned to either a low dose (1 mg) of tesamorelin — a lab-made version of a hormone that prompts the body to release growth hormone — or a placebo, given for 10 weeks. Neither group showed clear, statistically meaningful changes in memory and thinking tests, body composition, fatigue, sleep, or brain scans when analyzed the usual way. When the researchers applied advanced pattern-finding software, they spotted possible treatment-related differences in a few brain areas tied to thinking. The authors stress this was a small, early study designed mainly to test whether the combined approach of cognitive tests plus brain imaging and machine learning could pick up subtle effects. Its findings are preliminary and would need larger trials to confirm.